An Open-label, Dose-finding, Phase 1 Study to Assess the Safety, Tolerability, Efficacy, and Pharmacokinetic Profile, and to Explore the Pharmacodynamic Profile of DM5167 in Patients With Advanced Solid Tumors
Latest Information Update: 07 Aug 2025
At a glance
- Drugs DM 5167 (Primary)
- Indications Solid tumours; Triple negative breast cancer
- Focus Adverse reactions
- Sponsors DigmBio
Most Recent Events
- 07 Aug 2025 New trial record